{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:56:15Z","timestamp":1764831375267,"version":"3.46.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00417-025-06895-6","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T07:29:33Z","timestamp":1755242973000},"page":"3257-3270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An assessment of anti-VEGF drugs safety based on real-world data: from popularity to spontaneous reporting in eudravigilance database"],"prefix":"10.1007","volume":"263","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4968-0430","authenticated-orcid":false,"given":"Chen","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yicheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"6895_CR1","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(22)02609-5","volume":"401","author":"RH Guymer","year":"2023","unstructured":"Guymer RH, Campbell TG (2023) Age-related macular degeneration. Lancet 401:1459\u20131472","journal-title":"Lancet"},{"key":"6895_CR2","doi-asserted-by":"publisher","first-page":"8242","DOI":"10.3390\/ijms21218242","volume":"21","author":"F Ricci","year":"2020","unstructured":"Ricci F, Bandello F, Navarra P, Staurenghi G, Stumpp M, Zarbin M (2020) Neovascular Age-Related macular degeneration: therapeutic management and New-Upcoming approaches. Int J Mol Sci 21:8242","journal-title":"Int J Mol Sci"},{"key":"6895_CR3","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:e106\u2013e116","journal-title":"Lancet Glob Health"},{"key":"6895_CR4","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, Waheed NK, Chakravarthy U, Rosenfeld PJ, Holz FG et al (2020) Consensus nomenclature for reporting neovascular Age-Related macular degeneration data: consensus on neovascular Age-Related macular degeneration nomenclature study group. Ophthalmology 127:616\u2013636","journal-title":"Ophthalmology"},{"key":"6895_CR5","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1080\/14656566.2019.1636031","volume":"20","author":"H Al-Khersan","year":"2019","unstructured":"Al-Khersan H, Hussain RM, Ciulla TA, Dugel P (2019) U. Innovative therapies for neovascular age-related macular degeneration. Expert Opin Pharmacother 20:1879\u20131891","journal-title":"Expert Opin Pharmacother"},{"key":"6895_CR6","first-page":"513","volume":"117","author":"A Stahl","year":"2020","unstructured":"Stahl A (2020) The diagnosis and treatment of age-related macular degeneration. Dtsch Arztebl Int 117:513\u2013520","journal-title":"Dtsch Arztebl Int"},{"key":"6895_CR7","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte RS, Chen DS, Ferrara (2019) N. VEGF in signaling and disease: beyond discovery and development. Cell 176:1248\u20131264","journal-title":"Cell"},{"key":"6895_CR8","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2165\/00003495-200767080-00007","volume":"67","author":"SK Blick","year":"2007","unstructured":"Blick SK, Keating GM, Wagstaff AJ (2007) Ranibizumab. Drugs 67:1199\u20131206","journal-title":"Ranibizumab. Drugs"},{"key":"6895_CR9","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","volume":"37","author":"RL Avery","year":"2017","unstructured":"Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, Couvillion S, Nasir MA, Rabena MD, Maia M et al (2017) Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina 37:1847\u20131858","journal-title":"Retina"},{"key":"6895_CR10","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/1120672119832432","volume":"29","author":"Z Papadopoulos","year":"2019","unstructured":"Papadopoulos Z, Aflibercept (2019) A review of its effect on the treatment of exudative age-related macular degeneration. Eur J Ophthalmol 29:368\u2013378","journal-title":"Eur J Ophthalmol"},{"key":"6895_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/ICU.0000000000000849","volume":"33","author":"BL Kuo","year":"2022","unstructured":"Kuo BL, Singh RP (2022) Brolucizumab for the treatment of diabetic macular edema. Curr Opin Ophthalmol 33:167\u2013173","journal-title":"Curr Opin Ophthalmol"},{"key":"6895_CR12","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1007\/s40265-019-01231-9","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A (2019) Brolucizumab: first approval. Drugs 79:1997\u20132000","journal-title":"Drugs"},{"key":"6895_CR13","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","volume":"82","author":"M Shirley","year":"2022","unstructured":"Shirley M (2022) Faricimab: first approval. Drugs 82:825\u2013830","journal-title":"Drugs"},{"key":"6895_CR14","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/pharmaceutics13071102","volume":"13","author":"A Arrigo","year":"2021","unstructured":"Arrigo A, Bandello F (2021) Molecular features of classic retinal drugs, retinal therapeutic targets and emerging treatments. Pharmaceutics 13:1102","journal-title":"Pharmaceutics"},{"key":"6895_CR15","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3109\/02713683.2013.848899","volume":"39","author":"X Gu","year":"2014","unstructured":"Gu X, Yu X, Dai H (2014) Intravitreal injection of Ranibizumab for treatment of age-related macular degeneration: effects on serum VEGF concentration. Curr Eye Res 39:518\u2013521","journal-title":"Curr Eye Res"},{"key":"6895_CR16","first-page":"63","volume":"114","author":"A Machalinska","year":"2012","unstructured":"Machalinska A (2012) The impact of locally administrated VEGF inhibitors on vascular homeostasis\u2013controversies concerning safety of intravitreal therapy in AMD patients. Klin Oczna 114:63\u201367","journal-title":"Klin Oczna"},{"key":"6895_CR17","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s42081-022-00156-0","volume":"5","author":"K Togo","year":"2022","unstructured":"Togo K, Yonemoto N, Real World Data and Data Science in Medical Research (2022) Present and future. Jpn J Stat Data Sci 5:769\u2013781","journal-title":"Jpn J Stat Data Sci"},{"key":"6895_CR18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.jad.2021.10.009","volume":"296","author":"CW Hsu","year":"2022","unstructured":"Hsu CW, Tseng WT, Wang LJ, Yang YH, Kao HY, Lin PY (2022) Comparative effectiveness of antidepressants on geriatric depression: Real-World evidence from a Population-Based study. J Affect Disord 296:609\u2013615","journal-title":"J Affect Disord"},{"key":"6895_CR19","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1080\/10543406.2022.2152834","volume":"33","author":"T Lasky","year":"2023","unstructured":"Lasky T, Chakravarty A (2023) Real world data (RWD) in pediatrics. J Biopharm Stat 33:875\u2013880","journal-title":"J Biopharm Stat"},{"key":"6895_CR20","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.3346\/jkms.2018.33.e213","volume":"33","author":"HS Kim","year":"2018","unstructured":"Kim HS, Lee S, Kim JH (2018) Real-World evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci 33:e213","journal-title":"J Korean Med Sci"},{"key":"6895_CR21","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS (2018) Interpretation and impact of Real-World clinical data for the practicing clinician. Adv Ther 35:1763\u20131774","journal-title":"Adv Ther"},{"key":"6895_CR22","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40264-018-0647-1","volume":"41","author":"R Postigo","year":"2018","unstructured":"Postigo R, Brosch S, Slattery J, van Haren A, Dogn\u00e9 JM, Kurz X, Candore G, Domergue F, Arlett P (2018) EudraVigilance medicines safety database: publicly accessible data for research and public health protection. Drug Saf 41:665\u2013675","journal-title":"Drug Saf"},{"key":"6895_CR23","doi-asserted-by":"publisher","first-page":"e27712","DOI":"10.2196\/27712","volume":"4","author":"TE Sivesind","year":"2021","unstructured":"Sivesind TE, Szeto MD, Kim W, Dellavalle RP (2021) Google trends in dermatology: scoping review of the literature. JMIR Dermatol 4:e27712","journal-title":"JMIR Dermatol"},{"key":"6895_CR24","doi-asserted-by":"publisher","first-page":"e13439","DOI":"10.2196\/13439","volume":"5","author":"A Mavragani","year":"2019","unstructured":"Mavragani A, Ochoa G (2019) Google trends in infodemiology and infoveillance: methodology framework. JMIR Public Health Surveill 5:e13439","journal-title":"JMIR Public Health Surveill"},{"key":"6895_CR25","doi-asserted-by":"publisher","first-page":"e2306309","DOI":"10.1002\/advs.202306309","volume":"11","author":"Y Guo","year":"2024","unstructured":"Guo Y, Shen Z, Zhao W, Lu J, Song Y, Shen L, Lu Y, Wu M, Shi Q, Zhuang W et al (2024) Rational identification of novel Antibody-Drug conjugate with high bystander killing effect against heterogeneous tumors. Adv Sci 11:e2306309","journal-title":"Adv Sci"},{"key":"6895_CR26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3390\/ph16030455","volume":"16","author":"C Morgovan","year":"2023","unstructured":"Morgovan C, Dobrea CM, Chis AA, Juncan AM, Arseniu AM, Rus LL, Gligor FG, Ardelean SA, Stoicescu L, Ghibu S et al (2023) A descriptive analysis of direct oral anticoagulant drugs dosing errors based on spontaneous reports from the eudravigilance database. Pharmaceuticals 16:455","journal-title":"Pharmaceuticals"},{"key":"6895_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 18:427\u2013436","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6895_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11:3\u201310","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6895_CR29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10:483\u2013486","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6895_CR30","doi-asserted-by":"publisher","first-page":"100954","DOI":"10.1016\/j.preteyeres.2021.100954","volume":"84","author":"A Uemura","year":"2021","unstructured":"Uemura A, Fruttiger M, D\u2019Amore PA, De Falco S, Joussen AM, Sennlaub F, Brunck LR, Johnson KT, Lambrou GN, Rittenhouse KD et al (2021) VEGFR1 signaling in retinal angiogenesis and microinflammation. Prog Retin Eye Res 84:100954","journal-title":"Prog Retin Eye Res"},{"key":"6895_CR31","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/14740338.2023.2250717","volume":"23","author":"R Zhou","year":"2024","unstructured":"Zhou R, Lu P, He M, Chen J, Shi Y, Han F, Cai Y (2024) A real-world disproportionality analysis of anti-VEGF drugs from the FDA adverse event reporting system. Expert Opin Drug Saf 23:363\u2013371","journal-title":"Expert Opin Drug Saf"},{"key":"6895_CR32","doi-asserted-by":"publisher","first-page":"1017889","DOI":"10.3389\/fphar.2022.1017889","volume":"18","author":"P Ma","year":"2022","unstructured":"Ma P, Pan X, Liu R, Qu Y, Xie L, Xie J, Cao L, Chen Y (2022) Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS). Front Pharmacol 18:1017889","journal-title":"Front Pharmacol"},{"key":"6895_CR33","doi-asserted-by":"publisher","first-page":"1398783","DOI":"10.3389\/fphar.2024.1398783","volume":"15","author":"C Li","year":"2024","unstructured":"Li C, Lu Y, Song Z, Liu Y (2024) A real-world data analysis of ocular adverse events linked to anti-VEGF drugs: a WHO-VigiAccess study. Front Pharmacol 15:1398783","journal-title":"Front Pharmacol"},{"key":"6895_CR34","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1056\/NEJMct1000495","volume":"363","author":"JC Folk","year":"2010","unstructured":"Folk JC, Stone EM (2010) Ranibizumab therapy for neovascular age-related macular degeneration. N Engl J Med 363:1648\u20131655","journal-title":"N Engl J Med"},{"key":"6895_CR35","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ et al (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119:789\u2013801","journal-title":"Ophthalmology"},{"key":"6895_CR36","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","volume":"121","author":"JF Korobelnik","year":"2014","unstructured":"Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM et al (2014) Intravitreal Aflibercept for DME. Ophthalmology 121:2247\u20132254","journal-title":"Ophthalmology"},{"key":"6895_CR37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG et al (2020) HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of Brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127:72\u201384","journal-title":"Ophthalmology"},{"key":"6895_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000003003","volume":"41","author":"JS Heier","year":"2021","unstructured":"Heier JS, Singh RP, Wykoff CC, Csaky KG, Lai TYY, Loewenstein A, Schlott- mann PG, Paris LP, Westenskow PD, Quezada-Ruiz C (2021) The angiopoietin\/ tie pathway in retinal vascular diseases: a review. Retina 41:1\u201319","journal-title":"Retina"},{"key":"6895_CR39","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) MARINA study group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431","journal-title":"N Engl J Med"},{"key":"6895_CR40","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444","journal-title":"N Engl J Med"},{"key":"6895_CR41","first-page":"495","volume":"7","author":"M Thomas","year":"2013","unstructured":"Thomas M, Mousa SS, Mousa SA (2013) Comparative effectiveness of Aflibercept for the treatment of patients with neovascular age-related macular degeneration. Clin Ophthalmol 7:495\u2013501","journal-title":"Clin Ophthalmol"},{"key":"6895_CR42","doi-asserted-by":"publisher","first-page":"e022031","DOI":"10.1136\/bmjopen-2018-022031","volume":"9","author":"B Pham","year":"2019","unstructured":"Pham B, Thomas SM, Lillie E, Lee T, Hamid J, Richter T, Janoudi G, Agar- wal A, Sharpe JP, Scott A et al (2019) Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis. BMJ Open 9:e022031","journal-title":"BMJ Open"},{"key":"6895_CR43","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V et al (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399:729\u2013740","journal-title":"Lancet"},{"key":"6895_CR44","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","volume":"138","author":"AM Khanani","year":"2020","unstructured":"Khanani AM, Patel SS, Ferrone PJ, Osborne A, Sahni J, Grzeschik S, Basu K, Ehrlich JS, Haskova Z, Dugel PU (2020) Efficacy of every four monthly and quarterly dosing of faricimab vs Ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial. JAMA Ophthalmol 138:964\u2013972","journal-title":"JAMA Ophthalmol"},{"key":"6895_CR45","doi-asserted-by":"publisher","first-page":"9424","DOI":"10.3390\/ijms23169424","volume":"23","author":"S Liberski","year":"2022","unstructured":"Liberski S, Wichrowska M, Koci\u0119cki J (2022) Aflibercept versus faricimab in the treatment of neovascular Age-Related macular degeneration and diabetic macular edema: A review. Int J Mol Sci 23:9424","journal-title":"Int J Mol Sci"},{"key":"6895_CR46","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3341\/kjo.2014.28.1.32","volume":"28","author":"D Wang","year":"2014","unstructured":"Wang D, Choi KS, Lee SJ (2014) Serum concentration of vascular endothelial growth factor after bilateral intravitreal injection of bevacizumab. Korean J Ophthalmol 28:32\u201338","journal-title":"Korean J Ophthalmol"},{"key":"6895_CR47","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1097\/IAE.0b013e318213da43","volume":"31","author":"NR Acharya","year":"2011","unstructured":"Acharya NR, Sittivarakul W, Qian Y, Hong KC, Lee SM (2011) Bilateral efect of unilateral Ranibizumab in patients with uveitisrelated macular edema. Retina 31:1871\u20131876","journal-title":"Retina"},{"key":"6895_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0b013e318203c0ef","volume":"31","author":"KB Freund","year":"2011","unstructured":"Freund KB, Vance SK (2011) Systemic safety of bilateral intravitreal anti-vascular endothelial growth factor injections. Retina 31:1\u20133","journal-title":"Retina"},{"key":"6895_CR49","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s40259-021-00497-4","volume":"35","author":"WA Lee","year":"2021","unstructured":"Lee WA, Shao SC, Liao TC, Lin SJ, Lai CC, Lai EC (2021) Comparative risk of arterial thromboembolic events between afibercept and Ranibizumab in patients with maculopathy: a population-based retrospective cohort study. BioDrugs 35:579\u2013588","journal-title":"BioDrugs"},{"key":"6895_CR50","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","volume":"127","author":"CR Baumal","year":"2020","unstructured":"Baumal CR, Spaide RF, Vajzovic L, Freund KB, Walter SD, John V, Rich R, Chaudhry N, Lakhanpal RR, Oellers PR, Leveque TK, Rutledge BK, Chittum M, Bacci T, Enriquez AB, Sund NJ, Subong ENP, Albini TA (2020) Retinal vasculitis and intraocular inflammation after intravitreal injection of Brolucizumab. Ophthalmology 127:1345\u20131359","journal-title":"Ophthalmology"},{"key":"6895_CR51","doi-asserted-by":"publisher","first-page":"101521","DOI":"10.1016\/j.ajoc.2022.101521","volume":"26","author":"S Kusuhara","year":"2022","unstructured":"Kusuhara S, Kim KW, Miki A, Nakamura M (2022) Angiographic findings before and after the onset of brolucizumab-associated retinal vascular occlusion and intraocular inflammation. Am J Ophthalmol Case Rep 26:101521","journal-title":"Am J Ophthalmol Case Rep"},{"key":"6895_CR52","doi-asserted-by":"publisher","first-page":"eabq5241","DOI":"10.1126\/scitranslmed.abq5241","volume":"15","author":"AC Karle","year":"2023","unstructured":"Karle AC, Wrobel MB, Koepke S, Gutknecht M, Gottlieb S, Christen B, Rubic-Schneider T, Pruimboom-Brees I, Leber XC, Scharenberg M et al (2023) Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis\/retinal vascular occlusion adverse events. Sci Transl Med 15:eabq5241","journal-title":"Sci Transl Med"},{"key":"6895_CR53","doi-asserted-by":"publisher","first-page":"eabq5068","DOI":"10.1126\/scitranslmed.abq5068","volume":"15","author":"JD Kearns","year":"2023","unstructured":"Kearns JD, Wassmann P, Olgac U, Fichter M, Christen B, Rubic-Schneider T, Koepke S, de Cochin B, Ledieu D, Andre C et al (2023) A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic Brolucizumab. Sci Transl Med 15:eabq5068","journal-title":"Sci Transl Med"},{"key":"6895_CR54","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10384-021-00818-8","volume":"65","author":"K Kataoka","year":"2021","unstructured":"Kataoka K, Horiguchi E, Kawano K, Ushida H, Nakano Y, Ito Y, Terasaki H (2021) Three cases of brolucizumab-associated retinal vasculitis treated with systemic and local steroid therapy. Jpn J Ophthalmol 65:199\u2013207","journal-title":"Jpn J Ophthalmol"},{"key":"6895_CR55","doi-asserted-by":"publisher","first-page":"1132764","DOI":"10.3389\/fdata.2023.1132764","volume":"6","author":"R Alibudbud","year":"2023","unstructured":"Alibudbud R (2023) Google trends for health research: its advantages, application, methodological considerations, and limitations in psychiatric and mental health infodemiology. Front Big Data 6:1132764","journal-title":"Front Big Data"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06895-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-06895-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06895-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T05:02:59Z","timestamp":1764824579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-06895-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["6895"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-06895-6","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"type":"print","value":"0721-832X"},{"type":"electronic","value":"1435-702X"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that this study complies with all relevant ethical standards for research involving human data. All data analyzed were obtained from publicly available databases (Google Trends and EV) and did not involve direct human subject participation, thus not requiring institutional review board approval. No conflicts of interest, financial or otherwise, influenced the design, execution, or reporting of this research. No funding was received for this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}